Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P140002/S033

MISAGO RX Self-expanding Peripheral Stent

Terumo Medical Corporation · Decision date Feb 13, 2026

FDA DECISIONP140002/S033

What did the FDA decide?

FDA records P140002/S033 as a supplement to PMA P140002, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Feb 13, 2026.

FDA approval order statement

approval for an additional silicone oil manufacturer
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Feb 13, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P140002/S033
Regulatory pathway
PMA supplement
Product code
NIP
Decision code
OK30
Decision date
Feb 13, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: STENT, SUPERFICIAL FEMORAL ARTERY.

Product code
NIP
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P140002/S029 · Related supplement

    MISAGO RX Self-expanding Peripheral Stent; R2P Misago RX Self-expanding Peripheral Stent System

  2. P140002/S030 · Related supplement

    MISAGO RX Self-expanding Peripheral Stent

  3. P140002/S031 · Related supplement

    MISAGO RX Self-expanding Peripheral Stent

  4. P140002/S033 received

    Application receipt date recorded by FDA.

  5. P140002/S033 · FDA decision

    30-Day Notice

  6. P140002/S032 · Related supplement

    MISAGO(TM) RX Self-expanding Peripheral Stent

Timeline entries are records held by MedtechLedger for P140002. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P140002

Explore the linked device profile

Other records with product code NIP

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Terumo Medical Corporation

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
950 Elkton Blvd., Hatagaya, 151-0072

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records